Abstract
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disease that results in inflammation and structural destruction of the joints. A hallmark of RA pathogenesis is an imbalance of the osteoblast–osteoclast axis driven by inflammatory processes, resulting in elevated bone resorption by osteoclasts. Current therapies used to treat this disease have focused on inhibition of synovitis, but such treatments do not adequately repair damaged bone. A key pathway of osteoclast formation involves the receptor activator of nuclear factor κB ligand (RANKL) pathway acting on myeloid progenitor cells. The Wnt pathway has been shown to be important for the differentiation of osteoblasts from mesenchymal lineage precursors, and endogenous Wnt inhibitors, such as Dickkopf1 and sclerostin, might have important roles in osteoclast dysregulation in RA. Inhibition of the RANKL pathway, or blockade of Dickkopf1 and sclerostin, might serve to restore the osteoblast–osteoclast balance and repair bone erosion in RA joints. Such treatments, in combination with anti-inflammatory therapies, could stabilize and repair damaged joints and have the potential to be valuable additions to the armory of RA treatments.
Key Points
-
A hallmark of rheumatoid arthritis (RA) pathogenesis is an imbalance of the osteoblast–osteoclast axis, which is driven by inflammatory processes
-
Current treatments for RA target synovitis, but do not adequately target bone repair
-
The receptor activator of nuclear factor κB ligand (RANKL) pathway is a key driver of osteoclastogenesis, whilst the Wnt and bone morphogenetic protein pathways drive osteoblastogenesis
-
Dickkopf1 and sclerostin have been shown to act as endogenous inhibitors of the Wnt and bone morphogenetic protein axes
-
Targeting RANKL, Dickkopf1 and scelerostin might have clinical benefit in reducing bone destruction and enhancing repair of erosions in RA
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tak, P. P. & Bresnihan, B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 43, 2619–2633 (2000).
Walsh, M. C. et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33–63 (2006).
Combe, B. Progression in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 23, 59–69 (2009).
Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).
Smolen, J. S. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006).
Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).
Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793–2806 (2006).
Genovese, M. C. et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67, 547–554 (2008).
Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001–1009 (2000).
Breuil, V. & Euller-Ziegler, L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73, 349–354 (2006).
Romas, E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract. Res. Clin. Rheumatol. 19, 1065–1079 (2005).
Lard, L. R. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111, 446–451 (2001).
Genant, H. K. et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis. 67, 1084–1089 (2008).
Kubota, T., Michigami, T. & Ozono, K. Wnt signaling in bone metabolism. J. Bone Miner. Metab. 27, 265–271 (2009).
Chen, D., Zhao, M. & Mundy, G. R. Bone morphogenetic proteins. Growth Factors 22, 233–241 (2004).
Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
Suda, T. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345–357 (1999).
Glass, D. A. Jr et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751–764 (2005).
Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791–801 (2007).
Mundy, G. R. Osteoporosis and inflammation. Nutr. Rev. 65, S147–S151 (2007).
Bromley, M. & Woolley, D. E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 27, 968–975 (1984).
Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943–951 (1998).
Hashizume, M., Hayakawa, N. & Mihara, M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47, 1635–1640 (2008).
Dai, S. M., Nishioka, K. & Yudoh, K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann. Rheum. Dis. 63, 1379–1386 (2004).
Romas, E., Gillespie, M. T. & Martin, T. J. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30, 340–346 (2002).
Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345–1352 (1999).
Gravallese, E. M. et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250–258 (2000).
Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999).
Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673–2682 (2006).
Lam, J. et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481–1488 (2000).
Wei, S., Kitaura, H., Zhou, P., Ross, F. P. & Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115, 282–290 (2005).
Arron, J. R. et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J. Biol. Chem. 276, 30011–30017 (2001).
Kim, K. et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 280, 35209–35216 (2005).
Walsh, N. C. et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner. Res. doi:10.1359/jbmr.090320.
Williams, B. O. & Insogna, K. L. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J. Bone Miner. Res. 24, 171–178 (2009).
Guo, X. et al. Wnt/beta-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev. 18, 2404–2417 (2004).
Cheng, H. et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J. Bone Joint Surg. Am. 85-A, 1544–1552 (2003).
Miller, J. R. The Wnts. Genome Biol. 3, reviews3001.1–15 (2002).
Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).
Si, W. et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol. Cell. Biol. 26, 2955–2964 (2006).
Glinka, A. et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391, 357–362 (1998).
Bafico, A., Liu, G., Yaniv, A., Gazit, A. & Aaronson, S. A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 3, 683–686 (2001).
Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).
ten Dijke, P., Krause, C., de Gorter, D. J., Lowik, C. W. & van Bezooijen, R. L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint. Surg. Am. 90 (Suppl. 1), 31–35 (2008).
Lin, C. et al. Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. doi:10.1359/jbmr.090411.
van Bezooijen, R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805–814 (2004).
Winkler, D. G. et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem. 280, 2498–2502 (2005).
Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883–19887 (2005).
Semenov, M. V. & He, X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281, 38276–38284 (2006).
Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001).
Zwerina, J. et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50, 277–290 (2004).
Redlich, K. et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785–792 (2002).
Schett, G. et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48, 2042–2051 (2003).
Pettit, A. R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689–1699 (2001).
Bolon, B., Campagnuolo, G. & Feige, U. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell. Mol. Life Sci. 59, 1569–1576 (2002).
Kim, H. et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J. Clin. Invest. 119, 813–825 (2009).
Morvan, F. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006).
Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860–869 (2008).
Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
Eddleston, A. et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J. Bone Miner. Res. doi:10.1359/jbmr.090403.
Miller, P. D. Denosumab: anti-RANKL antibody. Curr. Osteoporos. Rep. 7, 18–22 (2009).
Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299–1309 (2008).
Cohen, G. et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann. Rheum. Dis. 66, 358–363 (2007).
Jacobson, J. A., Girish, G., Jiang, Y. & Resnick, D. Radiographic evaluation of arthritis: inflammatory conditions. Radiology 248, 378–389 (2008).
Sancho, E., Batlle, E. & Clevers, H. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol. 20, 695–723 (2004).
Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y. Choi declares no competing interests. J. Arron and M. Townsend are employees of Genentech.
Rights and permissions
About this article
Cite this article
Choi, Y., Arron, J. & Townsend, M. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 5, 543–548 (2009). https://doi.org/10.1038/nrrheum.2009.175
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.175
This article is cited by
-
Tau deficiency inhibits classically activated macrophage polarization and protects against collagen-induced arthritis in mice
Arthritis Research & Therapy (2023)
-
Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis
Zeitschrift für Rheumatologie (2023)
-
TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis
Nature Communications (2022)
-
Macrophages are the primary effector cells in IL-7-induced arthritis
Cellular & Molecular Immunology (2020)
-
Bone protection by inhibition of microRNA-182
Nature Communications (2018)